Stocks · Health care · Pharmaceutical Preparations

Enliven Therapeutics, Inc.

ELVN Clue Score23
United States Fiscal year ends December CIK 0001672619 Results filed 5 Nov 2026

What the insiders did Scheduled selling only

By person

10 insiders · 4 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Benjamin Hohl
Chief Financial Officer
—
$231.55K (1) scheduled
−$231.55K
38,000
0.0519%
$1.46M
—
Helen Louise Collins
Chief Medical Officer
—
$192.34K (1) scheduled
−$192.34K
25,000
0.0341%
$961.71K
—
Orbimed Advisors LLC entity
10% owner
—
—
—
6,555,102
8.95%
$252.16M
−14.8%
Samuel Kintz
President and CEO
—
—
—
890,392
1.22%
$34.25M
−11.1%
Joseph P Lyssikatos
Chief Scientific Officer
—
—
—
758,938
1.04%
$29.20M
−25.2%
Anish Patel
Chief Operating Officer
—
—
—
235,011
0.3207%
$9.04M
−31.5%
Lori Anne Kunkel
Director
—
—
—
52,925
0.0722%
$2.04M
+15.2%
Richard A. Heyman
Director
—
—
—
22,647
0.0309%
$871.19K
−42.0%
Mika K Derynck
Director
—
—
—
0
0.0000%
$0.00
—
J. Scott Garland
Director
—
—
—
0
0.0000%
$0.00
—